Department of Medicine–

Thomas Charles Merigan M.D.

Back to Profile

Publication Details

  • Multilocus genetic interactions and response to efavirenz-containing regimens: an adult AIDS clinical trials group study.

    Motsinger AA, Ritchie MD, Shafer RW, Robbins GK, Morse GD, Labbe L, Wilkinson GR, Clifford DB, D'Aquila RT, Johnson VA, Pollard RB, Merigan TC, Hirsch MS, Donahue JP, Kim RB, Haas DW. Pharmacogenet Genomics. 2006; 16 (11): 837-45

    For the HIV-1 reverse transcriptase inhibitor efavirenz, variant drug transporter gene ABCB1 may predict virologic response but not plasma efavirenz exposure. Conversely, variant drug metabolizing enzyme gene CYP2B6 predicts greater plasma efavirenz exposure but not virologic response. We examined whether long-term responses to efavirenz, and/or plasma efavirenz exposure, are better predicted by multilocus genetic interactions than by individual polymorphisms.

    PubMedID: 17047492

Stanford Medicine Resources:

Footer Links: